Paratek rises on takeout report

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) gained $5.20 (27%) to $24.25 on Wednesday after a Bloomberg report said the company is exploring strategic options, including a sale. The biotech did not respond to inquiries.

Paratek plans to complete submission of a rolling NDA to FDA in 1Q18 and to submit an MAA to EMA later in 2018 for omadacycline to treat acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP) (see BioCentury Extra, July 17)...